Key points are not available for this paper at this time.
Ten percent of patients abandon newly initiated oral oncolytics at the pharmacy. Patients facing higher cost sharing or increased concurrent prescription activity have a higher abandonment rate.
Streeter et al. (Sun,) studied this question.